A Study of LY3361237 in Participants With Psoriasis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

November 29, 2022

Study Completion Date

November 29, 2022

Conditions

Psoriasis

Interventions

DRUG

LY3361237

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (7)

Summit Clinical Research, s.r.o. - Bratislava, Bratislava

Budai Irgalmasrendi Korhaz, Budapest

MC Comac Medical, Sofia

All Med - Lodz, Lodz

Ai Centrum Medyczne Sp. Z O.O. Sp.K., Poznan

WIP Warsaw IBD Point Profesor Kierkus, Warsaw

Pratia - Warsaw, Warsaw

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT04975295 - A Study of LY3361237 in Participants With Psoriasis | Biotech Hunter | Biotech Hunter